Michel Finance
Chief Executive Officer presso Holding Incubatrice Biotechnologie
Profilo
Michel Finance currently works at Holding Incubatrice Biotechnologie, as Chairman & Chief Executive Officer, Prestizia SASU, as Chairman, France Biotech Association, as Director from 2006, and Truffle Capital SAS, as Venture Partner from 2010.
Mr. Finance also formerly worked at Theradiag SA, as CEO, Director & Head-Investor Relations in 2013, Zophis SASU, as Chairman, Biokinesis SAS, as Chairman, Affluent Medical SA, as Executive Chairman from 2022 to 2023, Flamel Technologies SA, as Deputy Managing Director in 2008, Sanofi, as Financial Director, Neovacs SA, as Executive Director from 2009 to 2015, Carmat SA, as Independent Director from 2008 to 2015, Aventis, Inc., as Controller & Senior Vice President, and PricewaterhouseCoopers Audit SA, as Financial Auditor.
Mr. Finance received his undergraduate degree from EM Lyon Business School.
Posizioni attive di Michel Finance
| Società | Posizione | Inizio |
|---|---|---|
France Biotech Association
 France Biotech Association Miscellaneous Commercial ServicesCommercial Services France Biotech Association is an independent association founded in 1997 that brings together healthtech entrepreneurs and their expert partners. The non-profit company is based in Paris, France. The association actively contributes to meeting the many challenges of the healthtech industry, such as companies' financing, innovation-related taxes, regulatory and market access related issues. It offers concrete competition and solutions through its commissions and working groups to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. The French company was founded by Philippe Pouletty, Pascal Brandys, Denis J. Lucquin. | Director/Board Member | 06/08/2010 |
Truffle Capital SAS
 Truffle Capital SAS Investment ManagersFinance Truffle Capital SAS is an Independent Venture Capital firm founded in 2000. Truffle Capital is headquartered in Paris. | Private Equity Analyst | 01/01/2010 |
Prestizia SASU
 Prestizia SASU Miscellaneous Commercial ServicesCommercial Services Part of Biosynex SA, Prestizia SASU is a French company that provides biotechnology research and development services. The private company is based in Paris, France. Odile Prigneau has been the CEO of the company since 2013. Prestizia was acquired by Theradiag SA, a subsidiary of Biosynex SA from Truffle Capital SAS on June 27, 2012. | Chairman | - |
| Holding Incubatrice Biotechnologie | Chief Executive Officer | - |
Precedenti posizioni note di Michel Finance
| Società | Posizione | Fine |
|---|---|---|
| AFFLUENT MEDICAL | Chief Executive Officer | 22/08/2022 |
| THERADIAG | Chief Executive Officer | 31/12/2018 |
| NEOVACS | Director/Board Member | 05/06/2015 |
| CARMAT | Director/Board Member | 20/03/2015 |
Flamel Technologies SA
 Flamel Technologies SA Pharmaceuticals: MajorHealth Technology Flamel Technologies SA engages in the research, development and commercialization of pharmaceutical products. Its portfolio includes Bloxiverz, Vazculep, Micropump, LiquiTime, Trigger Lock and Medusa. The company was founded by Gérard Soula in August 1990 and is headquartered in Vénissieux, France. | Corporate Officer/Principal | 01/01/2008 |
Formazione di Michel Finance
| EM Lyon Business School | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| SANOFI | Health Technology |
| NEOVACS | Health Technology |
| CARMAT | Health Technology |
| AFFLUENT MEDICAL | Health Technology |
| Aziende private | 10 |
|---|---|
Flamel Technologies SA
Flamel Technologies SA Pharmaceuticals: MajorHealth Technology Flamel Technologies SA engages in the research, development and commercialization of pharmaceutical products. Its portfolio includes Bloxiverz, Vazculep, Micropump, LiquiTime, Trigger Lock and Medusa. The company was founded by Gérard Soula in August 1990 and is headquartered in Vénissieux, France. | Health Technology |
| Aventis, Inc. | |
Theradiag SA
 Theradiag SA Medical SpecialtiesHealth Technology Theradiag SA engages in the distribution, development, and manufacturing of in vitro diagnostic and theranostics tests. It operates through the following segments: Theranostics and Diagnostics. The Theranostics segment offers solutions for patients treated with anti-tumour necrosis factor alpha. The Diagnostics segment includes products for anti-immunity, genetics, allergy, infectious disease, drug of abuse, other diagnoses, and instrumentation. The company was founded on December 29, 1986 and is headquartered in Croissy-Beaubourg, France. | Health Technology |
PricewaterhouseCoopers Audit SA
 PricewaterhouseCoopers Audit SA Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers Audit SA provides accounting, auditing and consulting services. The company was founded on February 10, 1967 and is headquartered in Neuilly-sur-Seine, France. | Commercial Services |
France Biotech Association
France Biotech Association Miscellaneous Commercial ServicesCommercial Services France Biotech Association is an independent association founded in 1997 that brings together healthtech entrepreneurs and their expert partners. The non-profit company is based in Paris, France. The association actively contributes to meeting the many challenges of the healthtech industry, such as companies' financing, innovation-related taxes, regulatory and market access related issues. It offers concrete competition and solutions through its commissions and working groups to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. The French company was founded by Philippe Pouletty, Pascal Brandys, Denis J. Lucquin. | Commercial Services |
Truffle Capital SAS
Truffle Capital SAS Investment ManagersFinance Truffle Capital SAS is an Independent Venture Capital firm founded in 2000. Truffle Capital is headquartered in Paris. | Finance |
| Holding Incubatrice Biotechnologie | Finance |
Prestizia SASU
Prestizia SASU Miscellaneous Commercial ServicesCommercial Services Part of Biosynex SA, Prestizia SASU is a French company that provides biotechnology research and development services. The private company is based in Paris, France. Odile Prigneau has been the CEO of the company since 2013. Prestizia was acquired by Theradiag SA, a subsidiary of Biosynex SA from Truffle Capital SAS on June 27, 2012. | Commercial Services |
Zophis SASU
 Zophis SASU BiotechnologyHealth Technology Zophis SASU operated as a holding company with interest in developing vaccine products. The company was founded in 2011 and was headquartered in Paris, France. | Health Technology |
Biokinesis SAS
 Biokinesis SAS BiotechnologyHealth Technology Biokinesis SAS provides research and development services. The firm specializes in Oncology. The company was founded in October 2011 and is headquartered in Paris, France. | Health Technology |
- Borsa valori
- Insiders
- Michel Finance
